Occurrences of thrombocytopenia with valproic acid used for psychiatric indication
Keywords:Thrombocytopenia, Valproate, Bipolar affective disorder, Schizophrenia
Background: The main aim of this study is to find out the effect of valproic acid on platelet count and to know the possible risk factors for thrombocytopenia in patients taking valproate (VPA).
Methods: On 72 patients having psychiatric indication, a longitudinal observational study was designed and conducted from February 2012 to July 2013 at Department of Psychiatry (out-patient department) of Pt. Jawahar Lal Nehru Memorial Medical College and Dr. Bhim Rao Ambedkar Memorial Hospital, Jail Road, Raipur, Chhattisgarh. Platelet count was monitored and determined using an automatic coulter analyzer. The patients were followed up to 6 months. Statistical tool standard deviation ± was used for statistical analysis. p<0.05 is considered as statistically significant.
Results: Total percentage of thrombocytopenia was found to be 12.5%; among that males constitute 9.8% and females 19.04%. The maximum number of cases falls in the age group between 51 and 60 years (55.5%). The major diagnostic group was reported to be consisted of mania (40.4%), followed by resistant cases of schizophrenia (25%) and then bipolar affective disorder (23.6%). The study indicated that maximum patients suffered from mild thrombocytopenia (11.1%) and (1.4%) patients have moderate thrombocytopenia. The mean time from exposure to VPA therapy to the first episode of thrombocytopenia was reported 92 days.
Conclusions: Our findings underlined the importance of monitoring platelet counts in patients treated with VPA. This monitoring should be continued indefinitely on monthly basis. The studies indicate that the demands of more vigilant monitoring of patients should occur in age of 50-60 years, and result of entire studies indicates that females were found to be subjected to incidences of thrombocytopenia especially.
Eliopoulos H. Thrombocytopenia Coincident With Depakote Therapy. Abbott Park, III, Abbott Pharmaceutical Products Division, Professional Information and Product Safety; 1993.
Neophytides AN, Nutt JG, Lodish JR. Thrombocytopenia associated with sodium valproate treatment. Ann Neurol. 1979;5(4):389-90.
Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy and polytherapy. Epilepsia. 1982;23(6):693-720.
Smith FR, Boots M. Sodium valproate and bone marrow suppression. Ann Neurol. 1980;8(2):197-9.
May RB, Sunder TR. Hematologic manifestations of long-term valproate therapy. Epilepsia. 1993;34(6):1098-101.
Delgado MR, Riela AR, Mills J, Browne R, Roach ES. Thrombocytopenia secondary to high valproate levels in children with epilepsy. J Child Neurol. 1994;9(3):311-4.
Winfield DA, Benton P, Espir ML, Arthur LJ. Sodium valproate and thrombocytopenia. Br Med J. 1976;2(6042):981.
Eastham RD, Jancar J. Sodium valproate and platelet counts. Br Med J. 1980;280(6208):186.
Calabrese JR, Markovitz PJ, Kimmel SE, Wagner SC. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol. 1992;12 1 Suppl:53S-6.
Tohen M, Castillo J, Baldessarini RJ, Zarate C Jr, Kando JC. Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. Am J Psychiatry. 1995;152(3):413-8.
Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, et al. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA. 1994;271(12):918-24.
Richardson SG, Fletcher DJ, Jeavons PM, Stuart J. Sodium valproate and platelet function. Br Med J. 1976;1:221-2.
von Voss H, Petrich C, Karch D, Schulz HU, Göbel U. Letter: sodium valproate and platelet function. Br Med J. 1976;2(6028):179.
Coulter DL, Wu H, Allen RJ. Valproic acid therapy in childhood epilepsy. JAMA. 1980;244(8):785-8.
Loiseau P. Sodium valproate, platelet dysfunction, and bleeding. Epilepsia. 1981;22(2):141-6.
Barr RD, Copeland SA, Stockwell ML, Morris N, Kelton JC. Valproic acid and immune thrombocytopenia. Arch Dis Child. 1982;57(9):681-4.
Ganick DJ, Sunder T, Finley JL. Severe hematologic toxicity of valproic acid. A report of four patients. Am J Pediatr Hematol Oncol. 1990;12(1):80-5.
Anderson GD, Lin YX, Berge C, Ojemann GA. Absence of bleeding complications in patients undergoing cortical surgery while receiving valproate treatment. J Neurosurg. 1997;87(2):252-6.
Conley EL, Coley KC, Pollock BG, Dapos SV, Maxwell R, Branch RA. Prevalence and risk of thrombocytopenia with valproic acid: experience at a psychiatric teaching hospital. Pharmacotherapy. 2001;21(11):1325-30.
Bharti AK. Incidences of thrombocytopenia in psychiatric population taking valproic acid: Demand’s clarification and attention. Int J Pharm Sci Rev Res. 2014;27(1):332-5.
Trannel TJ, Ahmed I, Goebert D. Occurrence of thrombocytopenia in psychiatric patients taking valproate. Am J Psychiatry. 2001;158(1):128-30.
Fawcett RG. Dose-related thrombocytopenia and macrocytic anemia associated with valproate use in bipolar disorder. J Clin Psychiatry. 1997;58(3):125.
Kaufman KR, Gerner R. Dose-dependent valproic acid thrombocytopenia in bipolar disorder. Ann Clin Psychiatry. 1998;10(1):35-7.
Hoffman LM. Sodium valproate and thrombocytopenia. Can Med Assoc J. 1982;126(4):358-9.
Vasudev K, Goswami U, Kohli K. Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology (Berl). 2000;150(1):15-23.
Kis B, Szupera Z, Mezei Z, Gecse A, Telegdy G, Vécsei L. Valproate treatment and platelet function: the role of arachidonate metabolites. Epilepsia. 1999;40(3):307-10.
Szupera Z, Mezei Z, Kis B, Gecse A, Vécsei L, Telegdy G. The effects of valproate on the arachidonic acid metabolism of rat brain micro vessels and of platelets. Eur J Pharmacol. 2000;387(2):205-10.
Chong BH. Drug-induced immune thrombocytopenia. Platelets 1991;2(4):173-81.
Rizvi MA, Shah SR, Raskob GE, George JN. Drug-induced thrombocytopenia. Curr Opin Hematol. 1999;6(5):349-53.